Brain Imaging Study in Subjects With Alzheimer Disease in Comparison to Healthy Subjects

Alzheimer's Disease Clinical Trial

Official title:

Evaluation of [123I] MNI-168 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00870519
• Other study ID #: MNI-168-01
• Status: Terminated
• Phase: Phase 1
• Start date: January 2009
• Est. completion date: December 2010

Study information

• Verified date: April 2019
• Source: Institute for Neurodegenerative Disorders
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The underlying goal of this study is to assess 123-I MNI-168 SPECT imaging as a tool to detect ß-amyloid deposition in the brain of Alzheimer's Disease (AD) research participants and similarly aged and gender matched healthy subjects.

Description:

The overall research questions to be addressed by this protocol are as follows:

• To assess the dynamic uptake and washout of (123I) MNI-168, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography (SPECT) in Alzheimer's (AD) subjects and similarly aged and gender matched healthy controls.

• To perform blood metabolite characterization of (123I) MNI-168 in healthy and AD subjects to determine the metabolic fate and nature of metabolites in assessment of (123I) MNI-168 as a single photon computed tomography (SPECT) brain imaging agent.

• To acquire initial safety data following injection of (123I) MNI-168.

• Obtain test/retest reproducibility information in AD subjects with (123I) MNI-168 based on initial studies.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 2
• Est. completion date: December 2010
• Est. primary completion date: December 2010
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

• Subjects who have a clinical diagnosis of AD will be recruited for this study

• The participant is 50 years or older

• Written informed consent is obtained

• Participants have a clinical diagnosis of probable Alzheimer's disease based on National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria

• Subjects will have a clinical dementia rating (CDR) assessment score of = 0.5 and < 2.0

• Modified Hachinski Ischemia Scale score of = 4

• For females, non-child bearing potential or negative urine and blood pregnancy test on day of 123-I MNI-168 injection

Exclusion Criteria:

• The subject has signs or symptoms of another neurodegenerative disease including Parkinson's disease, diffuse Lewy body dementia, or history of significant cerebrovascular disease

• The subject has clinically significant abnormal laboratory value and/or clinically significant unstable medical or psychiatric illness

• The subject has any disorder that may interfere with drug absorption distribution, metabolism, or excretion (including gastrointestinal surgery)

• The subject has evidence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, neoplastic, endocrine, neurological, immunodeficiency, pulmonary, or other disorder or disease

• The subject has participated in another clinical study within the previous 30 days

• Clinically significant MRI evidence of vascular disease or alternative neurologic disorder

• Pregnancy

Related Conditions & MeSH terms

• Alzheimer Disease
• Alzheimer's Disease

Intervention

Drug:
• I-123-MNI-168
Subjects will be injected with up to 5 mCi and not to exceed 5.5 mCi (not >10% of 5 mCi limit) of 123-I MNI-168 followed by serial SPECT imaging.
• 123-I MNI-168
Subjects will be injected with up to 5 mCi and not to exceed 5.5 mCi (not >10% of 5 mCi limit) of 123-I MNI-168 followed by serial SPECT imaging.

Locations

Country	Name	City	State
United States	Institute for Neurodegenerative Disorders	New Haven	Connecticut

Sponsors (1)

Lead Sponsor	Collaborator
Institute for Neurodegenerative Disorders

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To assess the uptake and washout of {I123}MNI-168, a potential imaging biomarker for ß-amyloid burden in brain,		1 year
Secondary	To acquire initial safety data following injection of (123I) MNI-168.		1 year